Rivastigmine

Symptomatic treatment of mild to moderately severe Alzheimer’s dementia. Symptomatic treatment of mild to moderately severe dementia in patients with idiopathic Parkinson’s disease.

JAMP

Rivastigmine Capsules (rivastigmine capsules) is indicated for: • The symptomatic treatment of patients with mild to moderate dementia of the Alzheimer's type. • JAMP Rivastigmine Capsules is indicated for the symptomatic treatment of patients with idiopathic Parkinson’s disease, and mild to moderate dementia, with onset at least 2 years after the initial diagnosis of Parkinson’s disease, and in whom other causes of dementia have been ruled out.

Rivastigmine capsule has not been studied in controlled clinical trials for longer than 6 months. JAMP Rivastigmine Capsules should only be prescribed by (or following consultation with) clinicians who are experienced in the diagnosis and management of dementia.

1 Pediatrics Pediatrics (< 18 years of age): No data are available to Health Canada; therefore, Health Canada has not authorized an indication for pediatric use. 2 Geriatrics Geriatrics (≥ 65 years of age): Dose escalation in patients >85 years old should proceed with caution.

Symptomatic treatment of mild to moderately severe Alzheimer’s dementia. Symptomatic treatment of mild to moderately severe dementia in patients with idiopathic Parkinson’s disease.

1 INDICATIONS AND USAGE EXELON PATCH is an acetylcholinesterase inhibitor indicated for treatment of: • Mild, moderate, and severe dementia of the Alzheimer’s type (AD). 1 ) • Mild-to-moderate dementia associated with Parkinson’s disease (PD).

1 Alzheimer’s Disease EXELON PATCH is indicated for the treatment of dementia of the Alzheimer’s type (AD). Efficacy has been demonstrated in patients with mild, moderate, and severe Alzheimer’s disease. 2 Parkinson’s Disease Dementia EXELON PATCH is indicated for the treatment of mild-to-moderate dementia associated with Parkinson’s disease (PDD).